|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
1/16/2013 9:18:39 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), a leading RNAi therapeutics company, today announced the pricing of an underwritten registered public offering of 8,000,000 shares of its common stock at a public offering price of $20.13 per share. All of the shares in the offering are to be sold by Alnylam. The offering is expected to close on or about January 22, 2013, subject to the satisfaction of customary closing conditions. J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC are acting as joint book-running managers and representatives of the underwriters for the offering. Deutsche Bank Securities Inc., Piper Jaffray & Co., Leerink Swann LLC, Needham & Company, LLC and JMP Securities LLC are acting as co-managers for the offering. Alnylam has granted the underwriters a 30-day option to purchase up to 1,200,000 shares to cover overallotments, if any.
|
|
|
|
|
|
|
|
|
|
|